Novo Nordisk, the Danish pharmaceutical company, is planning to launch its popular obesity drug, Wegovy, in Germany this month. However, the high costs and limited supply could hinder its rollout and impact patient access. While more than half of Germany’s population is overweight, the country’s strict legislation means that weight loss medications are not covered by public health insurance, forcing users to pay out-of-pocket. Wegovy is expected to cost between €170 and €300 per month in Germany, significantly lower than the US list price of $1,350. Nevertheless, the drug’s price still poses a challenge for public health systems in Europe. In Norway, Wegovy is not covered by the public health system, and in Denmark, it was rejected for public health insurance coverage due to its high cost. Supply constraints could also impact the drug’s momentum in the market. Novo Nordisk has advised German doctors to prescribe responsibly and limit prescriptions to patients with medical needs. The German Obesity Society, funded by Novo Nordisk, has called for public health systems to do more to extend treatment and prevention measures for obesity.
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
